NCT01125306|UnknownPhase 4
Loading search results
Sponsor study identifier
interventional
50
1 country
1
Study Start
June 2009
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
August 2011
Actual (reported)Study Completion
October 2012
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Xal-Ease is a novel Pfizer-Pharmacia device aimed to significantly facilitate the Xalatan/Xalacom instillation and to avoid loss of Xalatan/Xalacom eye drops due to incorrect instillation. Patients on Xalatan/Xalacom who have consumed more than one bottle per month within a year according to consumption data drawn from the Clalit Health Services database, will use the Xal-Ease device for a year. The device is expected to reduce consumption of bottles and result in saving money for both patients and medical care providers.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 2012
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 2009
Date type not reportedThis date has not been verified as actual or estimated.
May 16, 2010
Actual (reported)May 18, 2010
Actual (reported)August 2011
Actual (reported)October 2012
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Consumption of Xalatan/Xalacom bottles per year per patient.
12 months.
Evaluating cost of Xalatan/Xalacom eye drops use per year with Xal-Ease
12 months
Characterizing the optimal conditions for proper usage of the Xal-Ease device
12 months
Xal-Ease device used to facilitate application of Xalatan/Xalacom eye drops.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Ophthalmology department, Meir Medical Center
Kfar Saba, 44281, Israel
Semes L, Shaikh AS. Evaluation of the Xal-Ease latanoprost delivery system. Optometry. 2007 Jan;78(1):30-3. doi: 10.1016/j.optm.2006.06.016.
Nordmann JP, Baudouin C, Bron A, Denis P, Rouland JF, Sellem E, Renard JP. Xal-Ease: impact of an ocular hypotensive delivery device on ease of eyedrop administration, patient compliance, and satisfaction. Eur J Ophthalmol. 2009 Nov-Dec;19(6):949-56. doi: 10.1177/112067210901900609.
First Submitted
May 16, 2010
First Posted
May 18, 2010
Study Start
June 2009
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
August 2011
Actual (reported)How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?
Contact the study team to confirm eligibility.
Study Completion
October 2012
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
March 16, 2012
Record last verified: 2012-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: